相关实验视频

Updated: Jul 15, 2025

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head

Published on: September 27, 2024

在COVID-19大流行中,我们从类固醇治疗中学到的东西

A Yalci¹, E Doğan¹, M A Kapici¹

¹Department of Infectious Diseases and Clinical Microbiology, University of Health Science, Gülhane Educational and Research Hospital, Ankara, Turkey.

Nigerian journal of clinical practice

|October 4, 2023

概括

脉冲类固醇治疗 (PST) 在中度/严重的COVID-19肺炎患者中没有显著改变结果. 然而,PST在未接种疫苗的人群中显示了减少机械通风需求和死亡率,这表明需要进一步研究的潜在益处.

科学领域:

传染性疾病传染性疾病
肺部病理学肺部病理学
临界护理医学临界护理医学

背景情况:

由SARS-CoV-2引起的COVID-19大流行仍然是一个重大的全球健康挑战.
类固醇治疗是COVID-19感染管理的公认干预措施.
这项研究重点关注中度至重度的COVID-19肺炎的脉冲类固醇治疗 (PST).

研究的目的:

评估脉冲类固醇治疗 (PST) 对中度至重度COVID-19肺炎患者的炎症标志物和临床结果的影响.
评估PST在减少需要重症监护,机械呼吸和死亡率方面的有效性.
分析PST对不同人口分组的炎症标志物和患者结局的影响.

主要方法:

对因中度/重度COVID-19肺炎住院的成年患者的回顾性分析.
纳入标准基于世界卫生组织COVID-19指导方针.
收集的数据包括人口统计,治疗,炎症标志物,重症监护室入院,住院时间,高流量鼻氧,机械通风和死亡率.

主要成果:

接受PST的患者年龄较大,并有更多的并发症和更高的高流量鼻氧需求.
总体而言,在重症监护,住院,机械通风或PST和非PST组之间的死亡率方面没有发现统计学上显著的差异.
在未接种疫苗的患者中,PST与明显较低的机械通风需求和死亡率有关.

结论:

脉冲类固醇疗法 (PST) 在总死亡率或重症监护室 (ICU) 或机械通风 (MV) 要求方面没有显著的益处,对于COVID-19相关疾病的老年患者.
在未接种疫苗的COVID-19患者中,PST显示了降低MV要求和死亡率的潜在益处.
需要进一步的研究来确定PST在COVID-19治疗中的最佳剂量和应用协议.

关键词:

在 COVID-19 疫情中,脉冲类固醇的脉冲类固醇是什么治疗治疗治疗治疗治疗治疗

更多相关视频

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

相关概念视频

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Chronic Obstructive Pulmonary Disease-V: Management

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation

Pericarditis III: Medical Management

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...